Qlaira® Regulatory Post Marketing Surveillance Study in Korea

Trial Profile

Qlaira® Regulatory Post Marketing Surveillance Study in Korea

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Estradiol valerate/dienogest (Primary)
  • Indications Menorrhagia; Pregnancy
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Jun 2015 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
    • 14 Dec 2014 Planned number of patients changed from 720 to 750 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top